INVO Fertility Q1 sales beat estimates as losses widen
INVO Fertility reported Q1 revenue of $2.015 million, beating analyst estimates, while losses per share widened to $(3.38), missing expectations. Revenue growth of 23% was driven by organic initiatives and the Family Beginnings acquisition. The company strengthened its balance sheet, eliminating preferred stock liabilities and increasing cash to $4.9 million.
*this image is generated using AI for illustrative purposes only.
INVO Fertility reported a 23.09% increase in revenue to $2.015 million for the first quarter ended March 31, 2026, beating the analyst consensus estimate of $1.980 million by 1.77%. The company reported quarterly losses of $(3.38) per share, missing the analyst consensus estimate of $(1.25) by 170.4%. This represents a 99.78% increase over losses of $(1.50) per share from the same period last year. The growth was driven by organic initiatives and the acquisition of Family Beginnings, which added a fourth operational fertility clinic in the United States.
Financial Performance
Consolidated clinic revenue rose 22% to $1,982,233 from $1,621,553 in the prior-year period. Net loss from continuing operations was $(5.5) million, compared to $(1.5) million in Q1 2025. The 2026 period included a $3.8 million non-cash loss on changes in fair value related to liability-classified warrants that were reclassified to equity. Net loss was $(5.5) million, compared to $(17.4) million in the prior year, which included a $15.9 million loss from discontinued operations related to NAYA Therapeutics.
Adjusted EBITDA was $(1.26) million, compared to $(0.6) million, reflecting investments in personnel and infrastructure to support expansion. Stockholders' equity increased 108% to $15.0 million, or $9.16 per share, from $7.2 million at December 31, 2025. Total liabilities decreased 26% to $9.6 million, with current liabilities falling 39% to $6.4 million.
Operational Highlights
The company completed the acquisition of Family Beginnings in February 2026. Revenue growth was attributed to increased activity at the Georgia clinic and the partial-quarter contribution from Family Beginnings. The company added personnel across operations, human resources, and finance to support further expansion in 2026.
Strategic Outlook
Management emphasized the company's focus on two growth pillars: driving organic growth within existing clinics and pursuing disciplined acquisitions of established fertility practices. The divestiture of NAYA Therapeutics in 2025 resulted in a cleaner reporting period without losses from discontinued operations. The company believes it is better positioned to execute its long-term growth plan with a strengthened balance sheet and expanded clinic platform.
| Q1 2026 Financial Highlights | ||
|---|---|---|
| Metric | Q1 2026 | Q1 2025 |
| Total revenue | $2,015,225 | $1,637,185 |
| Clinic revenue | $1,982,233 | $1,621,553 |
| Net loss from continuing operations | $(5.5) million | $(1.5) million |
| Net loss | $(5.5) million | $(17.4) million |
| Adjusted EBITDA | $(1.26) million | $(0.6) million |
| Cash | $4.9 million | $2.1 million |
| Stockholders' equity | $15.0 million | $7.2 million |
What is the expected timeline for the Family Beginnings acquisition to become fully accretive to earnings?
How does INVO Fertility plan to bridge the gap between current revenue growth and future profitability?
Are there specific targets for additional clinic acquisitions or organic expansion for the remainder of 2026?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
